Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.60), $0.09 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $75 thousand, versus $158 thousand reported last year.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.